Drug Patents owned by Sun Pharm

1. Drug name - ABSORICA LD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750711 SUN PHARM Low dose oral pharmaceutical composition of isotretinoin May, 2035

(12 years from now)

US9700535 SUN PHARM Oral pharmaceutical composition of isotretinoin Aug, 2035

(12 years from now)

Drugs and Companies using ISOTRETINOIN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
8MG CAPSULE;ORAL Prescription
16MG CAPSULE;ORAL Prescription
20MG CAPSULE;ORAL Discontinued
24MG CAPSULE;ORAL Prescription
28MG CAPSULE;ORAL Discontinued
32MG CAPSULE;ORAL Prescription

2. Drug name - BROMSITE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778999 SUN PHARM Non-steroidal anti-inflammatory ophthalmic compositions Aug, 2029

(6 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.075% ACID SOLUTION/DROPS;OPHTHALMIC Prescription

3. Drug name - CEQUA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937225 SUN PHARM Topical formulations and uses thereof Aug, 2033

(10 years from now)

US8980839 SUN PHARM Topical aqueous nanomicellar, ophthalmic solutions and uses thereof Aug, 2033

(10 years from now)

US10441630 SUN PHARM Topical formulations and uses thereof Aug, 2033

(10 years from now)

US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof Feb, 2037

(14 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.09% SOLUTION;OPHTHALMIC Prescription

4. Drug name - DRIZALMA SPRINKLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9839626 SUN PHARM Duloxetine sprinkles Apr, 2037

(14 years from now)

US10413525 SUN PHARM Duloxetine sprinkles Apr, 2037

(14 years from now)

US10959982 SUN PHARM Duloxetine sprinkles Apr, 2037

(14 years from now)

US11202772 SUN PHARM Duloxetine sprinkles Apr, 2037

(14 years from now)

Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED REL PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE, DELAYED REL PELLETS;ORAL Prescription
EQ 30MG BASE CAPSULE, DELAYED REL PELLETS;ORAL Prescription
EQ 40MG BASE CAPSULE, DELAYED REL PELLETS;ORAL Prescription
EQ 60MG BASE CAPSULE, DELAYED REL PELLETS;ORAL Prescription

5. Drug name - EZALLOR SPRINKLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543 SUN PHARM Stable multiparticulate pharmaceutical composition of rosuvastatin Feb, 2036

(13 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 40MG BASE CAPSULE;ORAL Prescription

6. Drug name - INFUGEM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948 SUN PHARM Ready to be infused gemcetabine solution Jul, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1200MG BASE/120ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1300MG BASE/130ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1400MG BASE/140ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1500MG BASE/150ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1600MG BASE/160ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1700MG BASE/170ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1800MG BASE/180ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1900MG BASE/190ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2000MG BASE/200ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2200MG BASE/220ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

7. Drug name - ODOMZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178563 SUN PHARM Compounds and compositions as hedgehog pathway modulators
Jul, 2029

(6 years from now)

US8063043 SUN PHARM Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
Sep, 2029

(6 years from now)

CN101437800A SUN PHARM Compounds And Compositions As Hedgehog Pathway Modulators
Sep, 2013

(9 years ago)

CN102746285B SUN PHARM Compounds And Compositions As Hedgehog Pathway Modulators
May, 2027

(4 years from now)

CN102746285A SUN PHARM Compounds And Compositions Used As Hedgehog Pathway Modulators
May, 2027

(4 years from now)

CN102159570A SUN PHARM Salts Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide
Sep, 2029

(6 years from now)

CN102159570B SUN PHARM Salts Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide
Sep, 2029

(6 years from now)

IN301047B SUN PHARM N-(6-((2R, 6S)-2,6-Diethylmorpholino)Pyridin-3-Yl)-2-Methyl-4'- (Trifluoromethoxy)Biphenyl-3-Carboxamide
May, 2027

(4 years from now)

IN200809437P1 SUN PHARM Compounds And Compositions As Hedgehog Pathway Modulators
May, 2027

(4 years from now)

EP2363393B1 SUN PHARM Compounds And Compositions As Hedgehog Pathway Modulators
May, 2027

(4 years from now)

EP2363393A1 SUN PHARM Compounds And Compositions As Hedgehog Pathway Modulators
May, 2027

(4 years from now)

EP2021328A2 SUN PHARM Compounds And Compositions As Hedgehog Pathway Modulators
May, 2027

(4 years from now)

EP2021328B1 SUN PHARM Compounds And Compositions As Hedgehog Pathway Modulators
May, 2027

(4 years from now)

EP2342198A1 SUN PHARM A Diphosphate Salt Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide
Sep, 2029

(6 years from now)

EP2342198B1 SUN PHARM A Diphosphate Salt Of N-[6-Cis-2,6-Dimethylmorpholin-4Yl)Pyridine-3Yl]-2-Methyl-4'-(Trifluoromethoxy)[1,1'-Biphenyl]-3-Carboxamide
Sep, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE CAPSULE;ORAL Prescription

8. Drug name - RIOMET ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9962336 SUN PHARM Extended release suspension compositions May, 2035

(12 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
500MG/5ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Discontinued

9. Drug name - WINLEVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143240 SUN PHARM 17α, 21-dihydroxypregnene esters as antiandrogenic agents Jan, 2023

(3 months from now)

US9486458 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives Jul, 2028

(5 years from now)

US10159682 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives Aug, 2028

(5 years from now)

US11207332 SUN PHARM Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives Nov, 2028

(6 years from now)

US9433628 SUN PHARM Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives Feb, 2029

(6 years from now)

US8785427 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives Jul, 2030

(7 years from now)

Drugs and Companies using CLASCOTERONE ingredient

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

10. Drug name - XELPROS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539262 SUN PHARM Ophthalmic composition comprising a prostaglandin Oct, 2028

(6 years from now)

US9629852 SUN PHARM Ophthalmic composition comprising a prostaglandin Sep, 2029

(6 years from now)

Drugs and Companies using LATANOPROST ingredient

Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.005% EMULSION;OPHTHALMIC Prescription

11. Drug name - YONSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889144 SUN PHARM Abiraterone acetate formulation and methods of use Mar, 2034

(11 years from now)

US10292990 SUN PHARM Abiraterone steroid formulation May, 2034

(11 years from now)

Drugs and Companies using ABIRATERONE ACETATE ingredient

Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
125MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.